Similar effects were observed in a phase 0 study that investigated the in situ effects of subasumstat via trackable intratumor microdosing combined with spatial profiling in patients with head and neck cancer, in whom subasumstat was shown to modulate the TME from an immune-suppressive to an immune-permissive status through stimulation of the IFN pathway (22). Here, IFNA1 is linked to head and neck cancer.